Kristin Brooks04.30.21
Abbvie
1Q Revenues: $13 billion (+51%)
1Q Earnings: $3.6 billion (+18%)
Comments: Global revenues from the immunology portfolio were $5.7 billion, an increase of 13%. Humira revenues were $960 million, a decrease of 8% on a reported basis, due to biosimilar competition. Global Skyrizi revenues were $574 million, up 89%. Global Rinvoq revenues were $303 million, up over 100%. Global revenues from the hematologic oncology portfolio were $1.7 billion, an increase of 8% with Imbruvica revenues up 3% to $1.3 billion, and Venclexta revenues of $405 million, up 28%. Global revenues from the neuroscience portfolio were $1.2 billion, an increase of 11%, with Global Botox Therapeutic revenues of $532 million, up 7%, and Vraylar sales of $346 million, up 21%. Global revenues from the aesthetics portfolio were $1.1 billion, an increase of 35%, with Botox Cosmetic sales of $477 million, up 45%.
1Q Revenues: $13 billion (+51%)
1Q Earnings: $3.6 billion (+18%)
Comments: Global revenues from the immunology portfolio were $5.7 billion, an increase of 13%. Humira revenues were $960 million, a decrease of 8% on a reported basis, due to biosimilar competition. Global Skyrizi revenues were $574 million, up 89%. Global Rinvoq revenues were $303 million, up over 100%. Global revenues from the hematologic oncology portfolio were $1.7 billion, an increase of 8% with Imbruvica revenues up 3% to $1.3 billion, and Venclexta revenues of $405 million, up 28%. Global revenues from the neuroscience portfolio were $1.2 billion, an increase of 11%, with Global Botox Therapeutic revenues of $532 million, up 7%, and Vraylar sales of $346 million, up 21%. Global revenues from the aesthetics portfolio were $1.1 billion, an increase of 35%, with Botox Cosmetic sales of $477 million, up 45%.
